Patrick G. Schweickert
YOU?
Author Swipe
View article: Casdatifan (AB521) is a novel and potent allosteric small molecule inhibitor of protumourigenic HIF‐2α dependent transcription
Casdatifan (AB521) is a novel and potent allosteric small molecule inhibitor of protumourigenic HIF‐2α dependent transcription Open
Background and Purpose Hypoxia‐inducible factor 2α (HIF‐2α) is a transcription factor that mediates the expression of genes critical for cell adaptation and survival in low oxygen (hypoxic) conditions. In cancer, hypoxic conditions or mole…
View article: 1385 Dual Inhibition of DGKα and DGKζ increases T cell and NK cell activity
1385 Dual Inhibition of DGKα and DGKζ increases T cell and NK cell activity Open
Background Diacylglycerol kinases (DGKs) play a role in regulating the responsiveness of immune cells to activating stimuli, making them an emerging immunotherapeutic target. DGKs phosphorylate the signaling lipid diacylglycerol (DAG) to p…
View article: Supplementary Data from Thrombin Signaling Promotes Pancreatic Adenocarcinoma through PAR-1–Dependent Immune Evasion
Supplementary Data from Thrombin Signaling Promotes Pancreatic Adenocarcinoma through PAR-1–Dependent Immune Evasion Open
Table of differentially expressed genes from RNA-seq analysis of in vitro stimulation of KPC2 cells with and without thrombin.
View article: Supplementary Data from Thrombin Signaling Promotes Pancreatic Adenocarcinoma through PAR-1–Dependent Immune Evasion
Supplementary Data from Thrombin Signaling Promotes Pancreatic Adenocarcinoma through PAR-1–Dependent Immune Evasion Open
Supplementary Materials and Methods as well as Figures documenting TF-thrombin-PAR-1 driven PDAC disease progression.
View article: Data from Thrombin Signaling Promotes Pancreatic Adenocarcinoma through PAR-1–Dependent Immune Evasion
Data from Thrombin Signaling Promotes Pancreatic Adenocarcinoma through PAR-1–Dependent Immune Evasion Open
Pancreatic ductal adenocarcinoma (PDAC) is associated with robust activity of the coagulation system. To determine mechanisms by which clotting factors influence PDAC tumor progression, we generated and characterized C57Bl/6-derived KPC (K…
View article: Data from Thrombin Signaling Promotes Pancreatic Adenocarcinoma through PAR-1–Dependent Immune Evasion
Data from Thrombin Signaling Promotes Pancreatic Adenocarcinoma through PAR-1–Dependent Immune Evasion Open
Pancreatic ductal adenocarcinoma (PDAC) is associated with robust activity of the coagulation system. To determine mechanisms by which clotting factors influence PDAC tumor progression, we generated and characterized C57Bl/6-derived KPC (K…
View article: Supplementary Data from Thrombin Signaling Promotes Pancreatic Adenocarcinoma through PAR-1–Dependent Immune Evasion
Supplementary Data from Thrombin Signaling Promotes Pancreatic Adenocarcinoma through PAR-1–Dependent Immune Evasion Open
Table of differentially expressed genes from RNA-seq analysis of in vitro stimulation of KPC2 cells with and without thrombin.
View article: Supplementary Data from Thrombin Signaling Promotes Pancreatic Adenocarcinoma through PAR-1–Dependent Immune Evasion
Supplementary Data from Thrombin Signaling Promotes Pancreatic Adenocarcinoma through PAR-1–Dependent Immune Evasion Open
Supplementary Materials and Methods as well as Figures documenting TF-thrombin-PAR-1 driven PDAC disease progression.
View article: 258 AB308 is an anti-TIGIT antibody that enhances immune activation and anti-tumor immunity alone and in combination with other I-O therapeutic agents
258 AB308 is an anti-TIGIT antibody that enhances immune activation and anti-tumor immunity alone and in combination with other I-O therapeutic agents Open
Background TIGIT (T-cell immunoreceptor with Ig and ITIM domains) is an inhibitory receptor expressed on natural killer (NK) cells, CD8< sup >+ T cells, CD4< sup >+ T cells and regulatory T cells (T < sub >regs). On the surface of these ce…
View article: Investigating the respective roles of SOX9 and PAR1 in pancreatic ductal adenocarcinoma initiation and immune evasion
Investigating the respective roles of SOX9 and PAR1 in pancreatic ductal adenocarcinoma initiation and immune evasion Open
Pancreatic ductal adenocarcinoma (PDAC) is a poorly immune responsive, treatment refractory disease, representing the fourth leading cause of cancer deaths in the United States. A lack of significant improvements in patient prognoses over …
View article: Thrombin Signaling Promotes Pancreatic Adenocarcinoma through PAR-1–Dependent Immune Evasion
Thrombin Signaling Promotes Pancreatic Adenocarcinoma through PAR-1–Dependent Immune Evasion Open
Pancreatic ductal adenocarcinoma (PDAC) is associated with robust activity of the coagulation system. To determine mechanisms by which clotting factors influence PDAC tumor progression, we generated and characterized C57Bl/6-derived KPC (K…
View article: Induced <scp>PTF</scp>1a expression in pancreatic ductal adenocarcinoma cells activates acinar gene networks, reduces tumorigenic properties, and sensitizes cells to gemcitabine treatment
Induced <span>PTF</span>1a expression in pancreatic ductal adenocarcinoma cells activates acinar gene networks, reduces tumorigenic properties, and sensitizes cells to gemcitabine treatment Open
Pancreatic acinar cells synthesize, package, and secrete digestive enzymes into the duodenum to aid in nutrient absorption and meet metabolic demands. When exposed to cellular stresses and insults, acinar cells undergo a dedifferentiation …
View article: Genetic ablation of Smoothened in pancreatic fibroblasts increases acinar–ductal metaplasia
Genetic ablation of Smoothened in pancreatic fibroblasts increases acinar–ductal metaplasia Open
The contribution of the microenvironment to pancreatic acinar-to-ductal metaplasia (ADM), a preneoplastic transition in oncogenic Kras -driven pancreatic cancer progression, is currently unclear. Here we show that disruption of paracrine H…
View article: Plk1 inhibition enhances the efficacy of gemcitabine in human pancreatic cancer
Plk1 inhibition enhances the efficacy of gemcitabine in human pancreatic cancer Open
Gemcitabine is the standard-of-care for chemotherapy in patients with pancreatic adenocarcinoma and it can directly incorporate into DNA or inhibit ribonucleotide reductase to prevent DNA replication and, thus, tumor cell growth. Most panc…